
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to experience steady earnings growth, with anticipated GAAP earnings increasing to $4.73 per diluted share for full-year 2025 and $5.17 per diluted share for 2026, reflecting a positive outlook driven by the strength of its Human Nutrition and Health segment. The company reported 2Q25 top-line revenue of $255.5 million, which surpassed estimates and marked a 1% year-over-year increase, along with slight sequential growth from the previous quarter. Additionally, improvements in gross and net margins are expected, complemented by a potential debt-free status by the end of next year, positioning Balchem favorably for future strategic acquisitions given its strong balance sheet.
Bears say
Balchem Corp has experienced declining performance metrics, with the P/E multiple decreasing to 37.9x from 39.6x, suggesting diminished investor confidence. The company has exhibited slower-than-anticipated growth in its core segments, with missed revenue targets for both the Animal Nutrition and Health segment, which reported sales of $56.4 million compared to an estimate of $60 million, and the Specialty Products segment, which generated $1.4 million against an expected $1.6 million. Additionally, various risks, including inflationary pressures, difficulties in product launches, and potential disruptions in European operations, further exacerbate the negative outlook for Balchem's stock.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares